PMTA Ingredient Docs: What the Pouch Pilot Reveals

On December 19, 2025, the FDA issued Marketing Granted Orders for six on! PLUS nicotine pouch products from Helix Innovations: Mint, Tobacco and Wintergreen, each at 6 mg and 9 mg.

These were not the first authorized nicotine pouches. That was the 20 ZYN products FDA authorized on January 16, 2025, which the agency described at the time as the first occasion it had authorized products commonly referred to as nicotine pouches. What made the December orders different is that they were the first decisions out of FDA's nicotine pouch PMTA pilot, launched in September 2025 to compress review timelines through real-time communication with applicants rather than by relaxing the standard.

That distinction is worth more to an applicant than the "first authorization" framing it replaces. A review process built on real-time communication rewards exactly one thing: documentation that is complete and internally consistent when it is submitted. The mechanism that makes the review fast is a reviewer being able to close a question in days, which only works if the answer already exists in your file. For manufacturers with applications pending, or building one now, the question is the same: what did it take to get there?

The product formulations matter. The clinical data matters. But so does something that gets far less attention in the post-authorization analysis: the PMTA ingredient documentation package. Specifically, whether the evidence behind the nicotine source is complete enough to carry a reviewer through the manufacturing controls section without stopping.

Why These Authorizations Set the Bar

The ZYN orders in January 2025 established that a nicotine pouch PMTA could be granted at all. The pilot authorizations established something more useful to anyone still preparing a file: how quickly a complete application can move when the reviewer never has to stop and ask for something that should already be there. FDA completed the scientific review in roughly three months from the pilot's September launch.

Before that, applicants were working from principle rather than precedent. FDA's draft guidance, the proposed TPMP rule (88 FR 15174, published 10 March 2023, docket FDA-2013-N-0227, RIN 0910-AH91) and the Section 904 ingredient submission requirements described the standard. None of them showed what clearing it looked like from the inside.

Helix Innovations prepared applications that satisfied FDA reviewers across every required domain: product characterization, toxicological assessment, human behavioral data, and manufacturing controls. The manufacturing controls section is where ingredient documentation lives. That section does not get through review on assertions alone.

The proposed TPMP rule, and the material FDA published for the TPSAC meeting held on 18 May 2023 to discuss it, set out what manufacturing data the agency evaluates: pre-production design validation records, master manufacturing records (MMR), production records, ingredient specifications with corresponding certificates of analysis, and traceability documentation from raw material through finished product.

For pouches, nicotine is the active ingredient and the ingredient with the highest regulatory scrutiny. Every claim about nicotine content, purity, and uniformity in the application traces back to the ingredient supplier's documentation.

What FDA Reviews When It Reviews Your Nicotine Ingredient

The ingredient section of a PMTA is not a checkbox. FDA reviewers want to understand the nicotine source, its chemical characterization, how its quality is controlled batch-to-batch, and how those controls connect to the consistency claims made about the finished product.

Specifically, the documentation that supports a successful PMTA ingredient section includes:

Purity and characterization data. FDA does not require pharmacopoeial-grade nicotine for a tobacco product; the statutory standard is whether the product is appropriate for the protection of public health, not whether the ingredient carries a compendial label. What documenting against the USP and Ph. Eur. monographs buys you is a defined, externally set specification with published acceptance criteria and named test methods, which is a great deal easier to defend in review than a specification you wrote yourself.

Be precise about what those monographs actually say, because it comes up. They do not set the same window. The USP Nicotine monograph requires not less than 98.0% and not more than 102.0% of nicotine on the anhydrous basis; Ph. Eur. monograph 1452 requires 99.0% to 101.0% on the same basis. The 99.5%+ figure that appears on most commercial specifications is a supplier commitment set above both compendial floors, not the monograph limit for either. All three numbers belong in your file, each described as what it is.

What FDA is looking for underneath the headline figure is the impurity profile: the minor alkaloids and degradants quantified individually rather than rolled into a total. The compounds to report are the ones that travel with nicotine out of the leaf or form from it in storage: anatabine, beta-nicotyrine, cotinine, myosmine, nicotine N-oxide, nornicotine and anabasine, each against a named limit rather than rolled into a sum. A round assertion ("greater than 99%") raises questions. Specific batch data from an accredited laboratory, against a named method, does not.

Batch-specific COAs. Template certificates are not acceptable as PMTA support. Each batch referenced in the application needs its own certificate of analysis, identifying the batch number, analysis date, testing method, and results. If a manufacturer references nicotine from multiple production batches across their stability study, each batch needs documented purity data from that specific lot.

Impurity profile consistency. Batch-to-batch consistency in the nicotine source is what connects your ingredient data to the consistency claims you make about the finished product. A supplier whose minor alkaloid content sits comfortably inside its stated per-impurity limit on one delivery and several times that on the next has not given you a specification, they have given you a range of outcomes. That is a problem twice over: it is a quality issue, and it undermines the credibility of every consistency claim in the application that rests on it.

Source traceability. Under Section 904 of the Tobacco Control Act, manufacturers are required to submit ingredient listings. The nicotine source is a listed ingredient, and FDA expects documentation of its origin. Seed-to-shipment traceability covers the full chain: what tobacco varieties were grown where, how they were extracted, and how the purification chain was controlled. That documentation supports both the Section 904 submission and the manufacturing controls section of the PMTA. STC certification provides an independent audit trail that FDA reviewers can evaluate without having to take the manufacturer's word for it.

Tobacco Product Master Files (TPMF). The FDA allows ingredient and component suppliers to file a Tobacco Product Master File containing their confidential formulation and quality data. A manufacturer whose nicotine supplier has filed a TPMF can reference that file in their PMTA, allowing FDA reviewers to access the supplier's full technical package without it being disclosed to the applicant. For nicotine ingredient suppliers operating at the scale where multiple manufacturers rely on their product, a TPMF is the documentation infrastructure that makes cross-application consistency demonstrable to FDA.

The TPMP Framework: Still the Standard, Even Without a Final Rule

The FDA's proposed Tobacco Product Manufacturing Practice (TPMP) rule was published in the Federal Register on 10 March 2023, at 88 FR 15174 (docket FDA-2013-N-0227, RIN 0910-AH91). It has not been finalized. In the Unified Regulatory Agenda it sits under Long-Term Actions, and it has stayed there across successive editions of the agenda, which means no final rule is expected in the near term.

That does not change what FDA expects to see in a PMTA.

The TPMP rule described what FDA considers good manufacturing practice for tobacco and nicotine products: design controls, pre-production validation, personnel and training standards, facility requirements, quality systems, and batch traceability. These are not future requirements awaiting a final rule. They are the implicit standard against which FDA reviewers evaluate manufacturing controls in every PMTA submission. The on! PLUS authorizations demonstrated that meeting this standard is possible. They also confirmed what was already known: the manufacturers who get through review are the ones who built these systems before anyone made them mandatory.

For a nicotine pouch manufacturer building toward a PMTA, the practical question is not whether TPMP will be finalized. It is whether your manufacturing controls documentation, including your ingredient supplier documentation, would satisfy a reviewer who is benchmarking your application against those standards.

What This Means for Choosing a Nicotine Supplier

Manufacturers seeking PMTA authorization need a nicotine supplier whose documentation infrastructure supports the PMTA documentation package. That narrows the field considerably.

A supplier providing template COAs rather than batch-specific data is not PMTA-ready. A supplier who cannot produce traceability records from tobacco origin through the finished ingredient is not PMTA-ready. A supplier whose impurity profiles are inconsistent batch-to-batch creates a materials characterization problem that will surface in FDA review.

The criteria that distinguish a PMTA-ready nicotine supplier from a commodity ingredient provider are specific, and they are all things you can verify before you place an order rather than after. These are the checkpoints:

• Batch-specific COAs from an ISO 17025-accredited laboratory that name the method for every line, not just the result. The compendial assay is whichever procedure the monograph you are claiming compliance with prescribes, and a titrimetric result and a chromatographic result are not the same measurement, so a COA that prints an assay figure without naming the procedure behind it is not evidence of compendial compliance whatever the number says
• Full minor alkaloid and degradant profile across consecutive batches, reported individually rather than as a combined total. The working list is anatabine, beta-nicotyrine, cotinine, myosmine, nicotine N-oxide, nornicotine and anabasine
• Elemental impurity testing with individual measured values in µg/g for lead, arsenic, cadmium and mercury, not pass/fail only, and the method named (ICP-MS under USP 233 or Ph. Eur. 2.4.20). Note that ICH Q3D limits are permitted daily exposures in micrograms per day and vary by route of administration, so a bare ppm figure with no route and no daily dose behind it is not a limit; ask for the supplier's elemental impurity risk assessment alongside the numbers
• Residual solvent data compliant with ICH Q3C, with the specific extraction method documented
• Chain-of-custody documentation from tobacco source through nicotine extraction and purification
• ISO 9001, HACCP, and GMP-compliant manufacturing processes at the production facility
• Willingness to support a Tobacco Product Master File or provide equivalent documentation for PMTA reference

The risks of unverified suppliers extend beyond quality defects. A supplier who fails an audit mid-production is a supply chain crisis. A supplier whose documentation cannot support your PMTA filing is a regulatory crisis. Both categories of failure are more expensive than the cost of qualifying a supplier who can demonstrate compliance upfront.

The Documentation Gap Most Applicants Discover Late

One of the most consistent patterns in deficient PMTA submissions is the nicotine ingredient documentation gap. The FDA's deficiency letter process reveals what the agency considers insufficient: missing batch-specific data, gaps in impurity characterization, unverified traceability claims, and inconsistency between the nicotine ingredient as described in the application and the COA data on file.

The gap usually traces to a sourcing decision made before the PMTA process began. A manufacturer who selected their nicotine supplier based on price and availability, without verifying the documentation package against PMTA requirements, discovers the gap when it is expensive to fix. Replacing a nicotine supplier mid-development means new stability studies, new manufacturing controls validation, and a significantly delayed application timeline.

Qualifying the ingredient supplier early is what turns a supplier relationship into a documentation package that supports the filing instead of one that generates supplemental requests during review. None of that preparation is visible in the authorization data, which is precisely the problem: from the outside, an application that sailed through and an application that spent a year in deficiency correspondence look identical at the point of grant.

Practical Steps for Manufacturers Now

If your PMTA is in preparation or you are planning to file within the next two years, these steps address the ingredient documentation risk before it becomes a deficiency:

1. Request batch-specific COAs from your current supplier for the last five consecutive production batches. If the data shows inconsistency in minor alkaloid content or purity values, that is a materials characterization issue that needs to be addressed before, not during, FDA review.

2. Verify the extraction and purification process is documented. Can your supplier provide a process description that identifies the tobacco source, extraction method, purification steps, and analytical controls applied at each stage? If not, you have a traceability gap.

3. Ask about TPMF filing capability. If your supplier has not filed or is not willing to file a Tobacco Product Master File, understand what that means for your application. You will need to disclose ingredient information in your PMTA that your supplier may consider proprietary. Having that conversation before you file is better than discovering the conflict when you are assembling the application.

4. Confirm heavy metal and residual solvent testing methods. "We test for heavy metals" is not sufficient. "We test per ICH Q3D using ICP-MS with the following method, and here are the last five batch results" is sufficient.

These questions have specific answers, and a qualified supplier should be able to produce them on request.

NicAlliance is a US-based supplier offering 99.5%+ purity freebase nicotine (USP/EP-grade), nicotine salts, and nicotine bitartrate dihydrate with STC chain-of-custody traceability and batch-specific COAs from accredited laboratories. If you want to verify your current supplier against these criteria before filing, NicAlliance can provide batch-specific COAs, a TPMF filing overview, and a documentation gap assessment. Request a sample package or start the conversation with the NicAlliance team.

Frequently Asked Questions